A Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Efficacy, Safety and Pharmacokinetics of Voclosporin in Adolescents with Lupus Nephritis,
Role: PI,
Aurinia Pharmaceuticals, Inc.,
(09/2024 - 09/2025)
Status: Approved
A long-term, open-label follow-up study of tofacitinib for treatment of juvenile idiopathic arthritis (JIA),
Role: PI,
Pfizer Pharmaceuticals,
(05/2022 - 05/2023)
Status: Completed
Efficacy, safety and tolerability of tofacitinib for treatment of polyarticular course juvenile idiopathic arthritis (JIA) in children and adolescent subjects,
Role: PI,
Pfizer Inc., U.S. Pharmaceuticals Group,
(10/2018 - 10/2019)
Status: Completed
CMX001 350 A multicenter, open-label study of CMX001 treatment of serious diseases or conditions caused by dsDNA viruses,
Role: Investigator,
Chimerix, Inc,
(06/2012 - 06/2013)
Status: Completed
A phase II, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and pharmacokinetics of Obinutuzumab in adolescent patients with active class III or IV Lupus Nephritis, Including an Evaluation of Open-Label Safety and PK in a Cohort of Pediatric Patients (Aged 5 to,
Role: PI,
Hoffmann-La Roche Inc.,
(01/2025 - 01/2026)
Status: Approved
State
Song-Brown Healthcare Workforce Training Program Grant-THC SACHS,
Role: Faculty,
Office of Statewide Health Planning and Development,
(01/2020 - 09/2021)
Status: Closed